Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03494881 · ClinicalTrials.gov registry record · Early Phase 1
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03494881: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03494881 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03494881, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.
Interventions
- DRUG Nucala
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2025-02-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03494881
The ClinicalTrials.gov registry entry for NCT03494881 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nucala is the first listed.
NCT03494881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03494881 about?
NCT03494881 is a clinical study titled "Mepolizumab for the Treatment of Chronic Spontaneous Urticaria". This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.
What is the current status of trial NCT03494881?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-30. Estimated completion is 2025-02-25.
What interventions are being tested in trial NCT03494881?
The interventions under investigation include: Nucala (DRUG).
Who is sponsoring clinical trial NCT03494881?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.